ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$0.46 USD
0.00 (0.61%)
Updated May 2, 2024 03:58 PM ET
After-Market: $0.46 0.00 (0.02%) 7:44 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
ASLAN Pharmaceuticals Ltd. [ASLN]
Reports for Purchase
Showing records 1 - 20 ( 99 total )
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Positive Blinded Data in Dupilumab-Treated Eczema Patients; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Year-End Update on Clinical Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
New Data in Atopic Dermatitis and COPD Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
New TREK-AD Data Show Widening Placebo-Adjusted Efficacy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
EADV Presentation Reinforces Our Focus on Absolute Efficacy for Ebla
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Stats remain strong following data correction for Phase 2b TREK-AD
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
2Q23 Update; Eblasakimab Results In The Spotlight
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
TREK-AD Study Reports Positive Top-Line Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Shares Undervalued Following Phase 2b TREK-AD Results
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Positive Phase 2b TREK-AD Results Clear Path For Ebla Into Phase 3
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Phase 2b TREK-AD Preview and Scenario Analysis
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Eblasakimab Phase 1a Trial Data and Novel Mechanism Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Licensing Deal Inked for Eblasakimab in Japan; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Japan licensing agreement further validates eblasakimab ahead of key data
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D